ArticleAIDS (London, England)2017
Immediate initiation of cART is associated with lower levels of cerebrospinal fluid YKL-40, a marker of microglial activation, in HIV-1 infection.
Article in AIDS (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- Normalization of Soluble CD163 Levels After Institution of Antiretroviral Therapy During Acute HIV Infection Tracks with Fewer Neurological Abnormalities.The Journal of infectious diseases · 2018Trial
- Rapid decline of cerebrospinal fluid biomarkers of axonal injury and neuroinflammation after initiation of antiretroviral therapy in HIV.Journal of neurovirology · 2025Article
- Evaluation of the relationship between YKL-40 level and clinical severity in patients with Crimean-Congo hemorrhagic fever.Pathogens and global health · 2024Article
- Article
- Dysregulated neuroimmune interactions and sustained type I interferon signaling after human immunodeficiency virus type 1 infection of human iPSC derived microglia and cerebral organoids.bioRxiv : the preprint server for biology · 2023Article
- Article
- HIV viral transcription and immune perturbations in the CNS of people with HIV despite ART.JCI insight · 2022Article
- Neuroimaging the Neuropathogenesis of HIV.Current HIV/AIDS reports · 2021Review
- A longitudinal analysis of brain extracellular free water in HIV infected individuals.Scientific reports · 2021Article
- Very Early Initiation of Antiretroviral Therapy During Acute HIV Infection Is Associated With Normalized Levels of Immune Activation Markers in Cerebrospinal Fluid but Not in Plasma.The Journal of infectious diseases · 2019Article
- Glycoprotein YKL-40 Is Elevated and Predicts Disease Severity in Puumala Hantavirus Infection.Viruses · 2019Article
- Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection.Journal of neuroinflammation · 2019Article
- CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection.Neurology(R) neuroimmunology & neuroinflammation · 2019Article
- Molecular biomarkers of Alzheimer's disease: progress and prospects.Disease models & mechanisms · 2018Review
- Progressive Brain Atrophy Despite Persistent Viral Suppression in HIV Patients Older Than 60 Years.Journal of acquired immune deficiency syndromes (1999) · 2017Article
- Applying fluid biomarkers to Alzheimer's disease.American journal of physiology. Cell physiology · 2017Review
- High Number of Activated CD8+ T Cells Targeting HIV Antigens Are Present in Cerebrospinal Fluid in Acute HIV Infection.Journal of acquired immune deficiency syndromes (1999) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 2 countries.
Funding
Abstract
objectiveTo characterize cerebrospinal fluid (CSF) YKL-40, a unique biomarker that reflects activation of microglial cells, in acute (AHI) and chronic HIV-1 infection (CHI) and to determine the effect of treatment initiation on levels of this marker.
designA cross-sectional study of two groups of HIV-infected participants at baseline and follow-up timepoints.
methodsAHI (n = 33) and CHI (n = 34) participants underwent CSF and blood sampling before treatment initiation with combination antiretroviral therapy (cART) and at follow-up on cART in a subset of these individuals [6 months in AHI participants (n = 24), 1 year in CHI participants (n = 10)]. Measured parameters were analyzed at each timepoint. Analyses employed Mann-Whitney tests and Spearman correlations.
resultsBaseline median YKL-40 was higher in CHI than AHI (96844 versus 80754 ng/l; P = 0.011). Elevations in the CHI group relative to the AHI group persisted at follow-up despite treatment (87414 versus 66130 ng/l; P = 0.003). In untreated CHI, YKL-40 correlated with neopterin (r = 0.51, P = 0.0025), chemokine (CXC-motif) ligand-10 (r = 0.44, P = 0.011), and neurofilament light chain (r = 0.56, P = 0.0008) in CSF.
conclusionsThis study is the first to describe the dynamics of CSF YKL-40 in two groups of HIV-infected individuals before and after cART and demonstrates the value of this marker in understanding HIV neuropathogenesis. The results suggest the utility of further exploring the prognostic value of YKL-40, particularly in individuals with early HIV infection or those initiating treatment during CHI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.